Specialist healthcare investor Gilde Healthcare has agred to carve out blood group and immune reagents business Sanquin Reagents from Sanquin Health Solutions.
The post First deal from Gilde Healthcare’s €517m Fund IV sees firm carve out Sanquin Reagents first appeared on AltAssets Private Equity News.